miR-133a Promotes TRAIL Resistance in Glioblastoma via Suppressing Death Receptor 5 and Activating NF-κB Signaling
Recombinant tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), as a novel cancer therapeutic, is being tested in phase II and III clinical trials; however, TRAIL resistance remains a big obstacle preventing its clinical application. Considering that TRAIL-induced apoptosis throug...
Main Authors: | Shan-shan Wang, Lu Feng, Bao-guang Hu, Ying-fei Lu, Wei-mao Wang, Wei Guo, Chun-wai Suen, Bao-hua Jiao, Jian-xin Pang, Wei-ming Fu, Jin-fang Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-09-01
|
Series: | Molecular Therapy: Nucleic Acids |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253117302263 |
Similar Items
-
NF-κB, Mesenchymal Differentiation and Glioblastoma
by: Bakhtiar Yamini
Published: (2018-08-01) -
NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway
by: Jianyang Xiang, et al.
Published: (2022-01-01) -
Smad8 Is Increased in Duchenne Muscular Dystrophy and Suppresses miR-1, miR-133a, and miR-133b
by: Michael A. Lopez, et al.
Published: (2022-07-01) -
Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways
by: Mikel Gurrea-Rubio, et al.
Published: (2024-02-01) -
NPS-1034 Induce Cell Death with Suppression of TNFR1/NF-κB Signaling in Testicular Cancer
by: Jian-Ting Chen, et al.
Published: (2022-02-01)